CELsignia
FACT 1: Herceptin ® + Perjeta ® + AC-THP in Early-Stage HER2-Negative Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT03412643/FB-12)
FACT 2: Nerlynx ® + Paclitaxel + Carboplatin in Early-Stage Triple-Negative Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT03812393)
FACT 3: Xalkori ® + Vizimpro ® in Metastatic HER2-Negative Breast Cancer Patients Selected with the CELsignia MP Activity Test for HER2 and c-Met (NCT# not yet assigned)
FACT 4: Nerlynx ® + Faslodex ® in Metastatic HR-Positive Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT# not yet assigned)
FACT 6: Tabrecta ® + Nerlynx ® in Metastatic HER2-Negative Breast Cancer Patients Selected with the CELsignia MP Activity Test for HER2 and c-Met (NCT# not yet assigned)
Gedatolisib – Celcuity
Phase 1b study of Gedatolisib + Ibrance ®+ Endocrine Therapy in 1L/2L Metastatic ER-Positive, HER2-Negative Breast Cancer Patients (NCT02684032)
Gedatolisib – Investigator Sponsored
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER2-Positive Metastatic Breast Cancer (NCT03698383)